HPTN

(redirected from HIV Prevention Trials Network)
Also found in: Wikipedia.
AcronymDefinition
HPTNHIV Prevention Trials Network
References in periodicals archive ?
In addition, the HIV Prevention Trials Network (HPTN) is embarking on a study to test the feasibility of an enhanced "Test, Link to Care, Plus Treat" protocol (TLC-Plus) (HPTN 065, HPTN 2010).
These include the International Centers of Excellence in Research (ICERs), International Collaborations for Infectious Disease Research (ICIDRs), the Tropical Medicine Research Centers (TMRCs), the Tuberculosis Research Program, the HIV Vaccine Trials Network (HVTN), and the HIV Prevention Trials Network (HPTN).
These are among 60 US and international institutions that have been selected and that through the NIAID HIV/AIDS clinical trials networks--AIDS Clinical Trials Group, HIV Prevention Trials Network, HIV Vaccine Trials Network, International Maternal Pediatric Adolescent AIDS Clinical Trials Network, International Network for Strategic Initiatives in Global HIV Trials, and Microbicide Trials Network--will participate in research to address the highest priorities in HIV/AIDS prevention and treatment.
NIH's International HIV Prevention Trials Network is focusing on six key strategies, one of which homes in specifically on microbicides.
Researchers from the National Institutes of Health (NIH)-supported HIV Prevention Trials Network (HPTN) will present their results on Oct.
Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach.
WASHINGTON - Giving antiretroviral therapy early to HIV-positive patients is cost effective over a 5-year and lifetime horizon, according to a subanalysis of a large trial, the HIV Prevention Trials Network study number 052 (HPTN 052).
The study was conducted by the HIV Prevention Trials Network, largely funded by NIAID, and also received funding from the National Institute on Drug Abuse and the National Institute of Mental Health; the AIDS Clinical Trials Group, funded by NIAID, also provided support for the study.
Since 2007, he has served as a member of the Ethics Working Group of the HIV Prevention Trials Network.
PATH has the intent to conduct prophylaxis clinical trials in collaboration with partners including the HIV Prevention Trials Network. Following the completion of the clinical Phase 2 program, PATH and Janssen will evaluate entering into a late stage development agreement covering the use of rilpivirine as PrEP for uninfected individuals at high risk of acquiring HIV.